TABLE 1.
Baseline characteristics of the study cohort according to fluvoxamine use.
| Characteristic | Cohort participants | Received fluvoxamine | Not- received fluvoxamine | p value |
|---|---|---|---|---|
| No (Percent) | Number (Percent) | Number (Percent) | ||
| Total | 657 | 594 (90.6%) | 63 (9.4%) | |
| Sex | 0.761 | |||
| Female | 327 (49.8%) | 295 (49.7%) | 32 (50.8%) | |
| Male | 330 (50.2%) | 300 (50.5%) | 30 (47.6%) | |
| Mean Age | 48.1 years | 47.9 years | 49.7 years | 0.409 |
| Comorbidities | ||||
| Hypertension | 170 (25.8%) | 158 (26.6%) | 12 (19.0%) | 0.218 |
| Diabetes | 88 (13.4%) | 79 (13.3%) | 9 (14.2%) | 0.785 |
| Obesity | 202 (32.7%) | 185 (31%) | 17 (27%) | 0.697 |
| Dyslipidemia | 29 (4.4%) | 29 (4.8%) | 0 (0.0%) | 0.075 |
| Autoimmune | 36 (5.5%) | 34 (5.7%) | 2 (3.2%) | 0.413 |
| Heart disease | 11 (1.7%) | 11 (1.7%) | 0 (0%) | 0.276 |
| Lung disease | 26 (4%) | 25 (4.2%) | 1 (1.6%) | 0.310 |
| Vaccination Status | ||||
| Complete | 245 (37.3%) | 240 (40.4%) | 3 (4.7%) | <0.001 |
| Incomplete | 112 (17.0%) | 112 (18.9%) | 3 (4.7%) | 0.006 |
| Unvaccinated | 300 (45.8%) | 242 (40.7%) | 57 (90.5%) | <0.001 |
| Symptoms | ||||
| Fever | 195 (29.6%) | 173 (29.1%) | 22 (34.9%) | 0.425 |
| Arthralgia | 111 (16.9%) | 104 (17.5%) | 7 (11.1%) | 0.150 |
| Myalgia | 139 (21.1%) | 126 (21.2%) | 13 (20.6%) | 0.869 |
| Chest Tightness | 71 (10.8%) | 65 (10.9%) | 6 (9.5%) | 0.755 |
| Headache | 191 (29.1%) | 173 (29.1%) | 18 (28.6%) | 0.927 |
| Anosmia | 157 (23.9%) | 144 (24.2%) | 13 (20.6%) | 0.455 |
| Ageusia | 131 (19.9%) | 121 (20.4%) | 10 (15.8%) | 0.329 |
| Odynophagia | 122 (18.5%) | 107 (18.0%) | 15 (23.8%) | 0.301 |
| Dysgeusia | 34 (5.2%) | 31 (5.2%) | 3 (4.7%) | 0.997 |
| Rhinorrhea/cong | 151 (22.9%) | 141 (23.7%) | 10 (15.8%) | 0.207 |
| Hyporexia | 122 (18.5%) | 116 (19.5%) | 6 (9.5%) | 0.055 |
| Anorexia | 36 (5.5%) | 31 (5.2%) | 5 (7.9%) | 0.291 |
| Insomnia | 77 (11.7%) | 72 (12.1%) | 5 (7.9%) | 0.358 |
| Cough | 187 (28.5%) | 174 (29.3%) | 13 (20.6%) | 0.147 |
| Shortness of Breath | 70 (10.6%) | 57 (9.6%) | 13 (20.6%) | 0.003 |
| Expectoration | 49 (7.5%) | 43 (7.2%) | 6 (9.5%) | 0.614 |
| Diarrhea | 102 (15.5%) | 94 (15.8%) | 8 (12.7%) | 0.972 |
| Malaise | 213 (32.4%) | 189 (31.8%) | 24 (38.1%) | 0.297 |
| Nausea | 6 (0.9%) | 6 (0.9%) | 0 (0.0%) | -- |
| Vomiting | 2 (0.3%) | 2 (0.3%) | 0 (0.0%) | -- |
| Initial Covid Stage | ||||
| Mild | 554 (84.3%) | 497 (83.7%) | 57 (90.5%) | |
| Moderate | 102 (15.5%) | 98 (16.5%) | 4 (6.3%) | |
| Severe | 1 (0.15%) | 0 (0.0%) | 1 (1.6%) | |